Silence Therapeutics plc (SLN)

Market Cap	873.92M
Revenue (ttm)	33.86M
Net Income (ttm)	-44.79M
Shares Out	48.39M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	298,217
Open	18.62
Previous Close	18.74
Day's Range	17.80 - 18.70
52-Week Range	4.84 - 27.72
Beta	1.33
Analysts	Strong Buy
Price Target	61.50 (+240.53%)
Earnings Date	Aug 14, 2024

About SLN

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Craig A. Tooman M.B.A.
• Employees: 109
• Stock Exchange: NASDAQ
• Ticker Symbol: SLN

Financial Performance

In 2023, SLN's revenue was 25.38 million, an increase of 44.99% compared to the previous year's 17.50 million. Losses were -43.27 million, 6.86% more than in 2022.

Financial numbers in GBP

Analyst Forecast

According to 4 analysts, the average rating for SLN stock is "Strong Buy." The 12-month stock price forecast is $61.5, which is an increase of 240.53% from the latest price.

Price Target

$61.5

(240.53% upside)

Analyst Consensus: Strong Buy